ESR1 and breast carcinoma: Based on these findings, it is inviting to hypothesize that the ERα+ breast cancer tumors might contain a similar ERα− basal-like luminal progenitors that maintain the bulk of differentiated ERα+ tumor cells but themselves are refractory to anti-estrogen therapies and, therefore, ultimately contribute to the development of therapy resistance and tumor relapse.